Mark Gergen is Chief Executive Officer, President and Chairman of Poseida Therapeutics, Inc. (PSTX). The company reported total compensation of $3,818,018 for fiscal year 2023.
| Salary | $611,667 |
|---|---|
| Bonus | $0 |
| Stock awards | $1,442,285 |
| Option awards | $1,413,936 |
| Non-equity incentive plan | $336,420 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $13,710 |
| Total | $3,818,018 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Poseida Therapeutics, Inc. filed April 25, 2024, accession 0000950170-24-048291.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2023 | Chief Executive Officer, President and Chairman | $611,667 | $0 | $1,442,285 | $1,413,936 | $336,420 | $0 | $13,710 | $3,818,018 |
| FY2022 | Chief Executive Officer, President and Chairman | $565,750 | $0 | $1,696,700 | $1,752,012 | $342,280 | $0 | $12,710 | $4,369,452 |
Totals as disclosed in each year's own compensation disclosure for Poseida Therapeutics, Inc..
| Named executive officer | Role | FY2023 total |
|---|---|---|
| Mark Gergen this page | Chief Executive Officer, President and Chairman | $3,818,018 |
| Kristin Yarema | President, Cell Therapy | $2,434,565 |
| Brent Warner | President, Gene Therapy | $1,642,452 |
The company's named executive officers for fiscal year 2023, and what it reported for each. See the full Poseida Therapeutics, Inc. compensation brief.
Mark Gergen's compensation sits inside Poseida Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.